Parkinson's Disease Market Insight, Epidemiology and Market Forecast - 2028

Parkinson's Disease Market Insight, Epidemiology and Market Forecast - 2028

  • Pages: 100
  • Geography: Global
  • Delivery Timeline: 7-10 Business Days
  • Publication: Jan, 2019
  • SKU: DIMI0022
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

Parkinson's Disease Market Size | Parkinson's Disease Market Research Report 

DelveInsights ‘Parkinson's disease Market Insights, Epidemiology, and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Parkinson's disease in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Parkinson's disease from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2028

Parkinson's disease - Disease Understanding and Treatment Algorithm

The DelveInsight Parkinson's disease market report gives a thorough understanding of the Parkinson's disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides Parkinson's disease treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Parkinson's disease

The Parkinson's disease epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Parkinson's disease, Total Diagnosed Prevalence of Parkinson's disease, Gender-specific Diagnosed Prevalence of Parkinson's disease, Age-specific Diagnosed Prevalence of Parkinson's disease, and Stage-specific Prevalence of Parkinson's disease)  scenario of Parkinson's disease in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.

According to DelveInsight, the total number of diagnosed prevalent population of Parkinson's disease was found to be 1,373,639 in the year 2017.

Parkinson's disease Drug Chapters

This segment of the Parkinson's disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.          

There are currently no disease-modifying drugs for PD, but the treatments that are used can offer significant symptomatic relief of the motor symptoms. They offer little clinical benefit in terms of the nonmotor manifestations of PD. It is usual practice to delay the initiation of treatment until the patients symptoms become troubling, to reduce the impact of adverse effects. The present treatment options include medication, surgery, complementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy). The approved medication therapies are categorized into seven groups that includes Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists, MAO B inhibitors, Catechol O-methyltransferase (COMT) inhibitors, Anticholinergics, and Amantadine.

The drug to be used at the beginning of treatment of PD is either levodopa or a dopamine agonist. L-Dopa is a natural precursor of dopamine which is transformed in the brain into dopamine. It is the most effective available drug, although, after long-term use, complications can occur including motor fluctuations (an ‘on–off’ effect) and dyskinesias (abnormal involuntary movements), especially if high doses are taken over many years. In March 2017, the US food and drug administration (FDA) approved safinamide as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing “off” episodes.

Apart from the pharmacological therapies few companies are working in the development of gene and stem cell therapy, which can provide a cure to the disease.

Parkinson's disease Market Outlook

The Parkinson's disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Parkinson's disease in 7MM was found to be USD 1837.90 million in 2017 and is expected to increase at a CAGR of XX% from 2017-2028.

Parkinson's disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Parkinson's disease Report Insights

  •  Parkinson's disease Patient Population
  •  Parkinson's disease Therapeutic Approaches
  •  Parkinson's disease Pipeline Analysis
  •  Parkinson's disease Market Size and Parkinson's disease market trends
  •  Parkinson's disease Market Opportunities
  •  Impact of upcoming Therapies on Parkinson's disease 

Parkinson's disease Report Key Strengths

  • Parkinson's disease 10 Year Forecast
  • Parkinson's disease 7MM Coverage
  • Parkinson's disease Epidemiology Segmentation
  • Parkinson's disease Drugs Uptake
  • Highly Analyzed Parkinson's disease Market
  • Parkinson's disease Key Cross Competition

Parkinson's disease Report Assessment

  • Parkinson's disease Current Treatment Practices
  • Parkinson's disease Unmet Needs
  • Parkinson's disease Detailed Pipeline Product Profiles
  • Parkinson's disease Market Attractiveness
  • Parkinson's disease Market Drivers and Parkinson's disease Market Barriers

Key Benefits

  •  This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Parkinson's disease market
  •  Organize sales and marketing efforts by identifying the best opportunities for Parkinson's disease market
  •  To understand the future market competition in the Parkinson's disease market
     

1.    Key Insights
2.    Parkinson's Disease Market Overview at a Glance
2.1.     Market Share (%) Distribution of Parkinson's Disease in 2017
2.2.     Market Share (%) Distribution of Parkinson's Disease in 2028
3.    Parkinson's Disease: Disease Background and Overview
3.1.     Introduction
3.2.     Cause of Parkinson's Disease
3.3.     Signs and Symptoms of Parkinson's Disease
3.4.     Stages of Parkinson's Disease
3.5.     Risk Factors for Parkinson's Disease
3.6.     Classification of Parkinson's Disease
3.7.     Genetics of Parkinson's Disease
3.8.     Pathophysiology
3.9.     Diagnosis
3.9.1.  Diagnostic Guidelines
3.9.2.  American Academy of Family Physicians
3.9.3.  EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease
3.9.4.  The National Institute for Health and Care Excellence (NICE): Recommendation for Diagnosis of Parkinson's disease
3.9.5.  Diagnostic Algorithm
4.    Epidemiology and Patient Population
4.1.     Key Findings
4.2.     Total Prevalent Population of Parkinson's Disease (PD) in the 7MM
4.3.     Total Diagnosed Prevalent Population of Parkinson's Disease (PD) in the 7MM
4.4.     Gender- Specific Diagnosed Prevalence of Parkinson's Disease (PD) in the 7MM
4.5.     Age - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in the 7MM
4.6.     Type - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in the 7 MM
4.7.     Stage - Specific Diagnosed Prevalence of Parkinson's Disease in the 7MM
5.    Country Wise-Epidemiology of Parkinson's Disease
5.1.     United States Epidemiology
5.1.1.  Assumptions and Rationale
5.1.2.  Total Prevalent Population of Parkinson's Disease (PD) in the United States
5.1.3.  Total Diagnosed Prevalent Population of Parkinson's Disease (PD) in the United States
5.1.4.  Gender- Specific Diagnosed Prevalence of Parkinson's Disease (PD) in the United States
5.1.5.  Age - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in the United States
5.1.6.  Type - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in the United States
5.1.7.  Stage - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in the United States
5.2.     EU-5 Epidemiology
5.2.1.  Germany
5.2.1.1.  Assumptions and Rationale
5.2.1.2.  Total Prevalent Population of Parkinson's Disease (PD) in Germany
5.2.1.3.  Total Diagnosed Prevalent Population of Parkinson's Disease (PD) in Germany
5.2.1.4.  Gender- Specific Diagnosed Prevalent Cases of Parkinson's Disease (PD) in Germany
5.2.1.5.  Age - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Germany
5.2.1.6.  Type - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Germany
5.2.1.7.  Stage - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Germany
5.2.2.  France
5.2.2.1.  Assumptions and Rationale
5.2.2.2.  Total Prevalent Population of Parkinson's Disease (PD) in France
5.2.2.3.  Total Diagnosed Prevalent Population of Parkinson's Disease (PD) in France
5.2.2.4.  Gender- Specific Diagnosed Prevalence of Parkinson's Disease (PD) in France
5.2.2.5.  Age - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in France
5.2.2.6.  Type - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in France
5.2.2.7.  Stage - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in France
5.2.3.  Italy
5.2.3.1.  Assumptions and Rationale
5.2.3.2.  Total Prevalent Population of Parkinson's Disease (PD) in Italy
5.2.3.3.  Total Diagnosed Prevalent Population of Parkinson's (PD) Disease in Italy
5.2.3.4.  Gender- Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Italy
5.2.3.5.  Age - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Italy
5.2.3.6.  Type - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Italy
5.2.3.7.  Stage - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Italy
5.2.4.  Spain
5.2.4.1.  Assumptions and Rationale
5.2.4.2.  Total Prevalent Population of Parkinson's Disease (PD) in Spain
5.2.4.3.  Total Diagnosed Prevalent Population of Parkinson's Disease (PD) in Spain
5.2.4.4.  Gender- Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Spain
5.2.4.5.  Age - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Spain
5.2.4.6.  Type - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Spain
5.2.4.7.  Stage - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Spain
5.2.5.  United Kingdom
5.2.5.1.  Assumptions and Rationale
5.2.5.2.  Total Prevalent Population of Parkinson's Disease (PD) in the United Kingdom
5.2.5.3.  Total Diagnosed Prevalent Population of Parkinson's Disease in the United Kingdom
5.2.5.4.  Gender- Specific Diagnosed Prevalence of Parkinson's Disease in the United Kingdom
5.2.5.5.  Age - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in the United Kingdom
5.2.5.6.  Type - Specific Diagnosed Prevalence of Parkinson's Disease in the United Kingdom
5.2.5.7.  Stage - Specific Diagnosed Prevalence of Parkinson's Disease in the United Kingdom
5.3.     Japan Epidemiology
5.3.1.  Assumptions and Rationale
5.3.2.  Total Prevalent Population of Parkinson's Disease (PD) in Japan
5.3.3.  Total Diagnosed Prevalent Population of Parkinson's Disease (PD) in Japan
5.3.4.  Gender- Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Japan
5.3.5.  Age - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Japan
5.3.6.  Type - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Japan
5.3.7.  Stage - Specific Diagnosed Prevalence of Parkinson's Disease (PD) in Japan
6.    Treatment and Management of Parkinson's Disease
6.1.     Treatment algorithm
6.2.     Treatment Guidelines
6.2.1.  National Institute for Health and Care Excellence (NICE): Recommendation for Parkinson's disease
6.2.2.  EFNS/MDS-ES recommendations on therapeutic management of Parkinson's disease 2010
6.2.3.  American Academy of Family Physicians: Recommendations for Treatment of Parkinson's disease
6.2.4.  American Academy of Neurology (ANN): Parkinson's Disease Quality Measurement Set Update
7.    Unmet Needs
8.    Marketed Drugs
8.1.     Key Cross of Marketed Drugs
8.2.     Profiles of Some of the Marketed Drugs
8.3.     Istradefylline (KW6002): Kyowa Kirin
8.3.1.  Product Description
8.3.2.  Other Developmental Activities
8.3.3.  Clinical Development
8.3.4.  Clinical Trials Information
8.3.5.  Safety and Efficacy
8.3.6.  Product Profile
8.4.     Opicapone: BIAL
8.4.1.  Product Description
8.4.2.  Other Developmental Activities
8.4.3.  Clinical Development
8.4.4.  Clinical Trials Information
8.4.5.  Safety and Efficacy
8.4.6.  Product Profile
8.5.     Gocovri: Adamas Pharmaceuticals
8.5.1.  Product Description
8.5.2.  Other Developmental Activities
8.5.3.  Clinical Development
8.5.4.  Clinical Trials Information
8.5.5.  Safety and Efficacy
8.5.6.  Product Profile
8.6.     Xadago: Zambon SpA
8.6.1.  Product Description
8.6.2.  Other Developmental Activities
8.6.3.  Clinical Development
8.6.4.  Clinical Trials Information
8.6.5.  Safety and Efficacy
8.6.6.  Product Profile
8.7.     Osmolex ER: Osmotica Pharmaceutical
8.7.1.  Product Description
8.7.2.  Other Developmental Activities
8.7.3.  Clinical Development
8.7.4.  Clinical Trials Information
8.7.5.  Product Profile
8.8.     Duopa (Duodopa, ABT-SLV187): AbbVie
8.8.1.  Product Description
8.8.2.  Other Developmental Activities
8.8.3.  Clinical Development
8.8.4.  Clinical Trials Information
8.8.5.  Safety and Efficacy
8.8.6.  Product Profile
8.9.     Rytary: Impax Laboratories
8.9.1.  Product Description
8.9.2.  Regulatory Milestones
8.9.3.  Clinical Development
8.9.4.  Clinical Trials Information
8.9.5.  Safety and Efficacy
8.9.6.  Product Profile
8.10. Inbrija: Acorda Therapeutics
8.10.1.      Product Description
8.10.2.      Regulatory Milestones
8.10.3.      Clinical Development
8.10.4.      Clinical Trials Information
8.10.5.      Safety and Efficacy
8.10.6.      Product Profile
8.11. Nuplazid: ACADIA Pharmaceuticals Inc.
8.11.1.      Product Description
8.11.2.      Regulatory Milestones
8.11.3.      Clinical Development
8.11.4.      Safety and Efficacy
8.11.5.      Product Profile
9.    Emerging Drugs
9.1.     Key Cross of Emerging Drugs
9.2.     Apomorphine Infusion: US WorldMeds LLC
9.2.1.  Drug Description
9.2.2.  Other Developmental Activities
9.2.3.  Clinical Development
9.2.4.  Clinical Trials Information
9.2.5.  Product Profile
9.3.     Accordion Pill Carbidopa/Levodopa: Intec Pharma
9.3.1.  Drug Description
9.3.2.  Other Developmental Activities
9.3.3.  Clinical Developmental Activities
9.3.4.  Clinical Trials Information
9.3.5.  Safety and Efficacy
9.3.6.  Product Profile
9.4.     APL–130277: Sunovion Pharma
9.4.1.  Drug Description
9.4.2.  Other Developmental Activities
9.4.3.  Clinical Development
9.4.4.  Clinical Trials Information
9.4.5.  Safety and Efficacy
9.4.6.  Product Profile
9.5.     P2B001: Pharma Two B Ltd.
9.5.1.  Product Description
9.5.2.  Other Developmental Activities
9.5.3.  Clinical Development
9.5.4.  Clinical Trials Information
9.5.5.  Safety and Efficacy
9.5.6.  Product Profile
9.6.     IPX203: Impax Laboratories
9.6.1.  Drug Description
9.6.2.  Other Developmental Activities
9.6.3.  Clinical Developmental Activities
9.6.4.  Clinical Trial Information
9.6.5.  Safety and Efficacy
9.6.6.  Product Profile
9.7.     LY03003: Luye Pharma
9.7.1.  Product Description
9.7.2.  Other Developmental Activities
9.7.3.  Clinical Development
9.7.4.  Clinical Trials Information
9.7.5.  Product Profile
9.8.     ABBV-951: AbbVie
9.8.1.  Product Description
9.8.2.  Clinical Development
9.8.3.  Clinical Trials Information
9.8.4.  Product Profile
9.9.     NTCELL Implantation: Living Cell Technologies
9.9.1.  Product Description
9.9.2.  Other Developmental Activities
9.9.3.  Clinical Development
9.9.4.  Clinical Trials Information
9.9.5.  Safety and Efficacy
9.9.6.  Product Profile
9.10. Nilotinib: Novartis
9.10.1.      Product Description
9.10.2.      Other Developmental Activities
9.10.3.      Clinical Development
9.10.4.      Clinical Trials Information
9.10.5.      Safety and Efficacy
9.10.6.      Product Profile
9.11. Solriamfetol (JZP-110): Jazz Pharmaceuticals
9.11.1.      Product Description
9.11.2.      Other Developmental Activities
9.11.3.      Clinical Development
9.11.4.      Clinical Trials Information
9.11.5.      Safety and Efficacy
9.11.6.      Product Profile
9.12. AAV-GAD: Meira Gtx
9.12.1.      Product Description
9.12.2.      Other Developmental Activities
9.12.3.      Clinical Development
9.12.4.      Clinical Trials Information
9.12.5.      Safety and Efficacy
9.12.6.      Product Profile
9.13. OXB-102 (AXO-Lenti-PD): Axovant Sciences
9.13.1.      Product Description
9.13.2.      Other Developmental Activities
9.13.3.      Clinical Development
9.13.4.      Clinical Trials Information
9.13.5.      Safety and Efficacy
9.13.6.      Product Profile
9.14. ND0612: NeuroDerm
9.14.1.      Product Description
9.14.2.      Other development Activities
9.14.3.      Clinical Development
9.14.4.      Clinical Trials Information
9.14.5.      Safety and Efficacy
9.14.6.      Adverse Effects
9.14.7.      Product Profile
9.15. ITI-214: Intracellular Therapies
9.15.1.      Product Description
9.15.2.      Other development Activities
9.15.3.      Clinical Development
9.15.4.      Clinical Trials Information
9.15.5.      Safety and Efficacy
9.15.6.      Product Profile
9.16. IRL752: Integrative Research Laboratories AB (IRLAB)
9.16.1.      Product Description
9.16.2.      Other development Activities
9.16.3.      Clinical Development
9.16.4.      Clinical Trials Information
9.16.5.      Safety and Efficacy
9.16.6.      Product Profile
9.17. VY-AADC: Neurocrine Biosciences
9.17.1.      Product Description
9.17.2.      Other development Activities
9.17.3.      Clinical Development
9.17.4.      Clinical Trials Information
9.17.5.      Safety and Efficacy
9.17.6.      Product Profile
10.  Parkinson's Disease: 7 Major Market Analysis
10.1. Key Findings
10.2. Total Market Size of Parkinson's Disease in 7MM
10.3. Market Size of Parkinson's Disease by Therapies in 7MM
11.  Market Outlook: The United States
11.1. United States Market Size
11.1.1.      Total Market size of Parkinson's Disease
11.1.2.      Parkinson's Disease (PD) Market by Therapies
11.2. Market Outlook: Europe
11.2.1.      Germany
11.2.1.1.             Total Market size of Parkinson's Disease
11.2.1.2.             Parkinson's Disease Market by therapies
11.2.2.      France
11.2.2.1.             Total Market size of Parkinson's Disease
11.2.2.2.             Parkinson's Disease Market Size by Therapies
11.2.3.      Italy
11.2.3.1.             Total Market size of Parkinson's Disease
11.2.3.2.             Parkinson's Disease Market by therapies
11.2.4.      Spain
11.2.4.1.             Total Market size of Parkinson's Disease
11.2.4.2.             Parkinson's Disease Market by therapies
11.2.5.      United Kingdom
11.2.5.1.             Total Market size of Parkinson's Disease
11.2.5.2.             Parkinson's Disease Market by therapies
11.3. Market Outlook: Japan
11.3.1.      Total Market size of Parkinson's Disease
11.3.2.      Parkinson's Disease Market Size by therapies
12.  Market Drivers
13.  Market Barriers
14.  Appendix
14.1. Report Methodology
15.  DelveInsight Capabilities
16.  Disclaimer
17.  About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
 

Table 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Table 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Table 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Table 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Parkinson's Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Parkinson's Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Parkinson's Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Parkinson's Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Parkinson's Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Parkinson's Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Parkinson's Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Parkinson's Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Parkinson's Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Parkinson's Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Parkinson's Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Parkinson's Disease in France (2016-2028)
Figure 17: Treatable Cases of the Parkinson's Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Parkinson's Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Parkinson's Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Parkinson's Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Parkinson's Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Parkinson's Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Parkinson's Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Parkinson's Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Parkinson's Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Parkinson's Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Parkinson's Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Parkinson's Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 51: France-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Parkinson's Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Parkinson's Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Parkinson's Dis